Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study.

Journal: ESMO open
PMID: 39705838

Abstract

BACKGROUND: HER2-low expression has gained clinical relevance in breast cancer (BC) due to the availability of anti-HER2 antibody-drug conjugates for patients with HER2-low metastatic BC. The well-reported instability of HER2-low status during disease evolution highlights the need to identify patients with HER2-0 primary BC who may develop a HER2-low phenotype at relapse. In response to the urgency of maximizing treatment access, we utilized artificial intelligence to predict this occurrence.

Authors

  • F Miglietta
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • A Collesei
    Bioinformatics - Clinical Research Unit, Istituto Oncologico Veneto, IOV - IRCCS, Padova, Italy.
  • C Vernieri
    Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy; Oncology and Hemato-Oncology, Department University of Milan, Milan, Italy.
  • T Giarratano
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy.
  • C A Giorgi
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy.
  • F Girardi
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy.
  • G Griguolo
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • M Cacciatore
    Pathology Unit, ULSS 9 - Treviso-Azienda ULSS 2 Marca Trevigiana, Treviso, Italy.
  • A Botticelli
    Department of Radiological, Oncological and Pathological Science, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
  • A Vingiani
    Oncology and Hemato-Oncology, Department University of Milan, Milan, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • G Fotia
    Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy; Oncology and Hemato-Oncology, Department University of Milan, Milan, Italy.
  • F Piacentini
    Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy.
  • D Massa
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • F Zanghì
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • M Marino
  • G Pruneri
    Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • M Fassan
    Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Pathology Unit, Azienda Universitaria Ospedaliera di Padova, Padova, Italy.
  • A P Dei Tos
    Pathology Unit, Azienda Universitaria Ospedaliera di Padova, Padova, Italy.
  • M V Dieci
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Electronic address: mariavittoria.dieci@unipd.it.
  • V Guarneri
    Oncology Unit 2, Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Keywords

External Resources

Popular Topics
Recent Journals